NOVOCURE LTD (NVCR) Stock News

Jim Cramer Likes This Tech Stock: 'Terrific Business, Niche Business'

On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Keysight Technologies calling it a "Terrific business."

Mentions: LMT KEYS ADMA

Deep Dive Into NovoCure Stock: Analyst Perspectives (7 Ratings)

Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update

Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference

Why NovoCure Stock Was Winning Big This Week

Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025?

Mentions: ZLAB

Novocure Launches 40% After Pancreatic Cancer Treatment Succeeds

The company is soon to seek regulatory approval in the U.S. and abroad.

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Mentions: ZLAB

Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Novocure to Participate in Upcoming Investor Conferences

Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma

FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma

Novocure Appoints Christoph Brackmann as Chief Financial Officer

Novocure Reports Third Quarter 2024 Financial Results

Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment

The company could have a long path ahead to reimbursement and, ultimately, sales.

Mentions: MRK BMY

FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer

Novocure to Report Third Quarter 2024 Financial Results

Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy

Novocure Announces Planned CEO Transition